Results 161 to 170 of about 52,475 (270)

Thrombosis and bleeding outcomes with warfarin conversion to rivaroxaban during the COVID-19 pandemic

South African Medical Journal
Background. In 2020, during the coronavirus disease 2019 (COVID‐19) outbreak, eligible patients were converted from warfarin to rivaroxaban therapy to limit the transmission of COVID‐19 infection. Objective.
C-Y Wang, E Schapkaitz, S Louw, B Jacobson   +3 more
doaj   +1 more source

Micellar Liquid Chromatography Determination of Edoxaban in Oral Solid Dosage Forms: Theoretical Aspects and Validation

ChemMedChem, Volume 20, Issue 22, November 18, 2025.
A method is developed and validated to quantify edoxaban in solid oral dosage forms using micellar liquid chromatography. A chemometric strategy is used to study the retention mechanism. The procedure is green, economic, safe, and easy to handle; offers high sample throughput; and is reliable, thus useful for pharmaceutical quality control.
Juan Peris‐Vicente, Devasish Bose, Rajendra‐Pasad Pawar, Abhilasha Durgbanshi, Samuel Carda‐Broch   +4 more
wiley   +1 more source

Formulation and Evaluation of Cyclodextrin Loaded Rivaroxaban Fast Dissolving Tablets

, 2022
Trinadha Rao M, M. Raju, K. Swetha, J Jyosna, G Bhargav, PHANINDRA CVS, Akula Annapurna, Y. Srinivasa Rao   +7 more
openalex   +1 more source

Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study

, 2022
Seung‐Kee Min, Ji Sun Kim, Jang Yong Kim, Ui Jun Park, Taehoon Lee, Jin Mo Kang, Sun Cheol Park, Won-Il Choi, Ki Hyuk Park, Martin Gebel   +9 more
openalex   +2 more sources

Development of intracardiac thrombus in a young patient with antiphospholipid syndrome while she was on rivaroxaban: Case report and literature review [PDF]

, 2021
Elabbass Abdelmahmuod, Abdelrahman Hamad, Abdallah Almaghraby, Samah Mohamed, Maryam Alkuwari   +4 more
openalex   +1 more source

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF [PDF]

, 2013
W. Schuyler Jones, Anne S. Hellkamp, J. Halperin, Jonathan P. Piccini, G Breithardt, Daniel E. Singer, Keith A.A. Fox, Kenneth W. Mahaffey, Robert M. Califf, M R Patel   +9 more
openalex   +1 more source

BIOAVAILABILITY ENHANCEMENT STRATEGIES FOR RIVAROXABAN: A NOTEWORTHY REVIEW

, 2023
Adam A. Al-Shoubki, Mahmoud H. Teaima, Rehab Abdelmonem, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal   +4 more
openalex   +2 more sources

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [PDF]

, 2014
Al-Khatib, SM, Banerjee, A, Blendea, D, Camm, AJ, Conroy, JM, Cosio, FG, De Bono, J, G Cosio, MD, Guasch, E, Halperin, JL, Hess, PL, Kirchhof, P, Lip, GY, Nattel, S, Ruskin, J, Savelieva, I   +15 more
core   +1 more source

First experiences in the implementation of rivaroxaban in patients with pulmonary thromboembolism who received thrombolytic therapy [PDF]

, 2014
Slobodan Obradović, Boris Džudović, Snježana Vukotić, Danijela Vraneš, Miodrag Šipčić, Lidija Torbica, Nenad Ratković, Veljko Milić, Bojana Subotić, Anđelka Ristić   +9 more
openalex   +1 more source

Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation

, 2016
L. Silva Miguel, Jorge Ferreira
openalex   +1 more source